Limited Liability Company (LLC)
Immbionic
Immbionic Spółka z Ograniczoną Odpowiedzialnością
Limited Liability Company (LLC)
Immbionic Spółka z Ograniczoną Odpowiedzialnością
Immbionic Spółka z Ograniczoną Odpowiedzialnością (KRS 0000779473, NIP 9562348836) is a Polish company, headquartered in Toruń, Kujawsko-Pomorskie voivodeship. Immbionic operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since March 29, 2019. Immbionic's most recently reported net revenue was 181.8 K PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Other activities
IMMBIONIC.COM.PLCredibility rating
53.1 / 100
Average credibility
Insolvency risk
Low
Elevated threat
Closure risk
24
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/7 yrs
Board changes
1
1/7 yrs
PKD changes
0
0/7 yrs
Name changes
0
0/7 yrs
Data from 7 years of registry activity.
Payment reliability score from 2019–2024
Current: D (53/100)
Trend: stable (-1.0 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Standard limit from 2019–2024
Current: 48.6 K PLN
Safe: 14.6 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Founded
March 29, 2019
7 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
TORUŃ
KUJAWSKO-POMORSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
31 shares total
Shareholders
2
shareholders
Board
2 people
Filed years
6 years
2019–2024 · profitable: 5/6
Registry entries
21
latest: June 23, 2026
Risk signals
Revenue
181.8 K PLN
2024
Net profit
-32.9 K PLN
2024
Assets
343.5 K PLN
2024
Equity
343.3 K PLN
2024
EBITDA
-20.8 K PLN
2024
Valuation
273.2 K PLN
Low confidence
Low confidence
People holding roles at Immbionic according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
Rate business credibility - Immbionic.
No ratings
Explainer
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
Immbionic has 2 shareholders.
Yes - Immbionic's majority owner is "CENTRUM TRANSFERU TECHNOLOGII UMK" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ.
Immbionic's board has 2 members.
20 historical registry entries for Immbionic
Filing documents submitted (3 documents)
Filing documents submitted (3 documents)
Change in Section 1 (basic data)
TO.VII NS-REJ.KRS/9141/22/433/ADE
Filing documents submitted (3 documents)
Filing documents submitted (3 documents)
Latest reporting year
2025
Available years
7
Filing entries
0
Competing companies or those operating in the same market segment as Immbionic (industry: Research and development).
OLSZTYN· Research and development
Revenue 2024: 461.0 K PLN
INOWROCŁAW· Research and development
Revenue 2024: 300.1 K PLN
POZNAŃ· Research and development
Revenue 2024: 215.8 K PLN
CZĘSTOCHOWA· Research and development
Revenue 2024: 215.2 K PLN
OSTRÓW MAZOWIECKA· Research and development
Revenue 2024: 124.0 K PLN
WARSZAWA· Research and development
Revenue 2024: 117.2 K PLN
